Although development of C3a antagonists remains limited and improved pharmacological tools to block the C3a receptor are still lacking (1), future studies could employ C3aR knockout mice to further investigate whether C3a plays a critical role in mediating AT1-AA–induced preeclampsia-like symptoms. This evidence concerns the gene C3AR1 and preeclampsia.